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Plan-of-the-day
Dose surface maps
Radiotherapya b s t r a c t
Background and purpose: To investigate relationships between patient-reported acute gastro-intestinal
symptoms in a locally advanced cervical cancer (LACC) prospective cohort and clinical and dosimetric
parameters, while also taking spatial dose into account.
Material and methods: A total of 103 patients was included, receiving radiotherapy based on a
plan-library-based plan-of-the-day protocol, combined either with concurrent chemotherapy or with
neo-adjuvant chemotherapy and concomitant hyperthermia. Toxicity endpoints were extracted from
questionnaires sent out weekly during treatment and regularly in the acute phase after treatment.
Endpoints were defined for symptoms concerning obstipation, diarrhea, fecal leakage, bowel cramps
and rectal bleeding. Dose surface maps were constructed for the rectum. Clinical parameters and
dosimetric parameters of the bowel bag and rectum were collected for all patients.
Results: The use of concomitant chemotherapy and an increase in Planning Target Volume (PTV) resulted
in a significant increase in reported diarrhea. The dose–volume parameters V5Gy–V25Gy of the rectum
were found to be significant, unlike dose–volume parameters of the bowel bag. Additionally, a
significantly higher dose to the inferior part of the rectum was found for patients reporting diarrhea.
No significance was reached for fecal leakage and bowel cramps.
Conclusion: The significance of results for patients reporting diarrhea symptoms found for PTV volume
indicates a potential benefit for a plan-of-the-day protocol. Additionally, the results suggest that a reduc-
tion of inferior rectum dose could decrease patient-reported diarrhea symptoms, while the administration
of concomitant chemotherapy appears to lead to radiosensitizing effects that increase these symptoms.
 2020 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 148 (2020) 38–43
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).In the treatment of locally advanced cervical cancer (LACC)
patients, the current treatment of choice is the administration of
external beam radiotherapy (EBRT) with concomitant chemother-
apy and image-guided adaptive brachytherapy. Research has
shown that this patient group suffers from a variety of side effects
caused by the treatment. Patients report, among others, gastroin-
testinal (GI) toxicity, genitourinary (GU) toxicity and overall
decrease in quality of life (QoL) in both the acute and late phase
after treatment [1]. Dose–response relationships are most often
physician-scored, based on scales defined by the Radiation Therapy
Oncology Group/European Organization for Research andTreatment of Cancer (RTOG/EORTC) or in accordance with
Common Terminology Criteria for Adverse Events (CTCAE) [2–4].
However, Patient-Reported Outcomes (PROs) are increasingly used
for toxicity reporting, as physician-scored toxicity often underesti-
mates patients’ perception of the toxicity burden [4]. As PROs
comprise the patient’s perception of the toxicity burden, a
dose–response model for PROs would capture this effect.
For GI toxicity within pelvic cancer cohorts, most research
shows a relationship between dose–volume parameters and
physician-assessed acute diarrhea symptoms on the RTOG/EORTC
or CTCAE scales [2,3,5]. GI symptoms can affect patients’ QoL and
can stay persistent throughout follow-up [6,7]. As it is known for
prostate cancer patients that acute GI toxicity symptoms are a sig-
nificant predictor for late GI morbidity, special focus ought to be
spent to decrease the occurrence of acute symptoms in LACC-
cohorts [8]. Additionally, research has shown that the spatial con-
figuration of the dose distribution, described by e.g. Dose Surface
Maps (DSMs), can offer a more comprehensive view than solely
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way, which has been demonstrated for physician-graded late tox-
icity prediction in various studies [13–15]. Currently, no studies
have been performed on correlations between dose and patient-
reported GI toxicity in the acute treatment phase of a LACC-
cohort. In prostate cancer cohorts, planned dose to inferior rectum
has been found to be of influence for multiple acute patient-
reported GI toxicity endpoints [9,16].
In this paper, we investigated relationships between clinical
and planned dosimetric parameters and acute patient-reported
GI toxicity. To include the possible influence of spatial effects,
DSMs of rectum were constructed. To our knowledge, this is the
first time these endpoints are investigated for a LACC-cohort trea-
ted with a library-of-plans based protocol.
Methods and materials
Locally advanced cervical cancer patients in our institute have
been enrolled in a library-of-plans based Plan-of-the-Day (PotD)
protocol since 2012. A prospective cohort study was started after
approval of the local ethics committee (MEC-2012-586). Patients
were included after providing Informed Consent. Patients were
treated between January 2012 and February 2018 in the Erasmus
MC. QoL-questionnaires were sent out to patients at fixed points
before, during, and after their radiation treatment.Patient population and treatment
The patients included in this study received five cycles of
concomitant (cisplatin) chemotherapy and radiotherapy
(image-guided external beam radiotherapy and brachytherapy),
abbreviated to CTRT, or six cycles of neo-adjuvant (paclitaxel/
carboplatin) chemotherapy with radiotherapy (image-guided
external beam radiotherapy and brachytherapy) and concomitant
hyperthermia, abbreviated to NeoCT + HTRT. As part of the PotD
protocol in our institute [17], patients were classified as movers
or non-movers for their EBRT schedule, depending on the differ-
ence in uterus position between full and empty bladder. Patients
were classified as a mover, when the tip of the uterus was dis-
placed more than 2.5 cm between full and empty bladder CT scan.
Since May 2014 rectum laxation with suppositories was added to
the CT protocol [6]. An Internal Target Volume (ITV) was
constructed based on these CT scans, after which a 1-cm margin
was applied to construct the Planning Target Volume (PTV).
Non-movers received one library plan encompassing the ITV from
full to empty bladder, and a backup plan in case the library plan
would not suffice. Movers received two library plans on top of
the backup plan, one encompassing the uterus position from
empty to half-full bladder, and one library plan based on half-full
to full bladder. Library plans were delivered with IMRT before
2014, and after 2014 with VMAT. Patients received 45–48.6 Gy
(1.8–2.0 Gy per fraction) with EBRT. At the end of external beam
treatment patients were scheduled to receive 17–21 Gy
(7.0–8.5 Gy per fraction) with brachytherapy. For further details
we refer to Sharfo et al. and Heijkoop et al. [17,18].Toxicity reporting
Patients were asked to fill in the EORTC QLQ-C30 and QLQ-CX24
questionnaires [19,20], which were sent out in before, during, and
after treatment. For this study the GI-related questions were con-
sidered (referring to Q16, Q17, Q31, Q32, and Q33 of the combined
questionnaire). This comprised the following questions:
1. Have you had constipation? (constipation)
2. Have you had diarrhea? (diarrhea)3. Have you had cramps in your abdomen? (bowel cramps)
4. Have you had difficulty in controlling your bowels? (fecal
leakage)
5. Have you had blood in your stools? (rectal bleeding)
Baseline data was defined as data reported at baseline or, when
unavailable, at week 1 of external beam radiotherapy treatment. As
this study focused on acute effects, maximum QoL deterioration
was defined as the highest increase of score from baseline reported
in either week 2, week 3, week 4, week 5 of radiotherapy, 1 week
after completion of radiotherapy, 1 month after completion or
3 months after completion. Dichotomization was performed per
question to create a binary classification for analysis. The questions
allowed answers on a four-point scale, allowing a maximum possi-
ble deterioration of three points from baseline. Deterioration of
two or three points was classified as a toxicity due to irradiation.
Improvement, stabilization or deterioration of one point was con-
sidered not to be clinically significant.
The impact of the use of antidiarrheal drugs, which can affect
diarrhea symptoms, is considered to be mitigated by investigating
the maximum deterioration from baseline. By only taking into con-
sideration a deterioration of two or more points, we aimed to only
include clinically relevant worsening of symptoms.Evaluation of dose distribution
Only external beam radiation dose was taken into account for
analysis. Heijkoop et al. showed that most patients reached peak
toxicity in week 3 and week 4 of treatment for GI symptoms, at
which point no brachytherapy or sequential external beam boost
had been delivered yet [6]. Dosimetric information was taken from
the half-full to full bladder library plan in case the patient was clas-
sified a mover, and from the single library plan if the patient was
classified to be a non-mover. The physical dose distribution was
converted to a 2 Gy-equivalent dose using the linear-quadratic
model (a/b = 10 for acute effects) to account for different fraction-
ation schemes [21].
Investigated OARs were the rectum and bowel bag, due to the
focus on GI toxicity in this study. Delineations were made on the
full bladder CT scan. The rectum structure was delineated from
the ischial tuberosities up to the recto-sigmoid junction. The bowel
bag was contoured to 3 cm above PTV according to EMBRACE II
guidelines (outer contour bowel loops, including the mesentery)
to encompass dose levels of 15 Gy and higher [22], and also
included the sigmoid. Examples of delineations are displayed in
Supplementary S.1. From the dose distribution dosimetric parame-
ters were extracted for all patients for rectum, bowel bag and the
Posterior–Inferior Border of Symphysis (PIBS) point as anatomical
vaginal reference point. As the delineations of the rectum were
based on anatomical landmarks, relative dose–volume parameters
were considered. For bowel bag the absolute dose–volume param-
eters (in cc) were considered, as the interpatient bowel bag volume
differed greatly due to the chosen superior delineation boundary.
Dose Surface Maps (DSMs) were made for the rectum, based on
the strategy described by Hoogeman et al. [23]. The rectal structure
as delineated on the planning CT was reduced to a central axis with
a fixed number of equidistant (along the central axis) planes to
describe the rectal curvature. On the cross-sections of the planes
with the rectal structure, the planes were virtually unfolded along
the dorsal side and resampled to an isotropic grid. Afterwards, the
high dose regions of all patients were aligned and overlaid, in order
to be robust to anatomical differences in uterus-to-rectum posi-
tion. DSMs were constructed for all patients, after which average
DSMs grouped by toxicity scoring were constructed. Significance
testing was performed as described by Chen et al. [24]. A dose dif-
ference map corrected by the standard deviation was computed
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tions). For each permutation the 95th percentile of the corrected
dose difference was computed, after which statistically significant
regions were marked. Possible confounding in results was investi-
gated with the help of a correlationmatrix of DSM values on an iso-
tropic evaluation grid. DSM analyses were done for the entire
cohort, and for the two treatment groups separately.Statistical analysis
All parameters were tested for significance with Fisher’s exact
test for binary variables or Wilcoxon test for continuous variables.
Odds ratios were calculated with univariate logistic regression.
Spearman’s rank correlation coefficient was applied to investigate
local dose dependence in DSMs. Statistical significance was defined
as p < 0.05. Statistical analyses were performed with MATLAB
(Mathworks version 2017a).
Results
A total of 103 patients was included for this study based on the
selection criteria. An overview of the patient characteristics can be
found in the Table S.2 (Supplementary S.2). QoL data was collected
for all patients and described time points, after which the maxi-
mum deterioration from baseline was computed. Patients filled
in a median of 5 questionnaires. The overall incidence of a deteri-
oration of two points or more was 10% for constipation, 59% for
diarrhea, 36% for bowel cramps, 16% for fecal leakage and 2% for
rectal bleeding. A graphical representation of the deterioration
levels of all questions can be found in Fig. 1. Due to the relatively
small cohort size and low incidence of constipation and rectal
bleeding, statistical power for these symptoms was lacking. Conse-
quently, neither of these symptoms was further analyzed.
PTV volume and the distance of the lower bound of the rectum
structure to the PTV (LBRectum-PTV) were found to be significant forFig. 1. Response rates for GI-related questions in QLQ-C30 and QLQ-CX24. Deterioration
phase, and can be three at maximum due to the four-point scale of the questions.diarrhea symptoms, as well as treatment group (Table 1). When
the treatment groups were considered individually, results per-
sisted for PTV volume within the CTRT group, but not for LB-
Rectum-PTV, while Dmean, Rectum reached significance. For the
NeoCT + HTRT group separately no parameters reached signifi-
cance. For bowel cramps and fecal leakage no parameters were
found to be significant for the treatment groups separately, and
combined.
DVH curves for the entire cohort are displayed in Fig. 2 for
rectum or bowel bag, split by toxicity endpoint. A Wilcoxon test
was performed per dose point of 1 Gy for the volumes of both
the toxicity and no toxicity group, in order to identify possibly
significant dose regions. The figures indicate a significant report-
ing in toxicity for dose values in the range of V5Gy–V25Gy for
diarrhea symptoms and in the region of V15Gy–V20Gy for bowel
cramps, both for the rectum structure. On the other hand, no
significant relationships were found between bowel bag dose
and toxicity endpoints. Spatial dose differences between end-
points for the entire cohort became visible with the help of
DSMs in Fig. 3. For diarrhea complaints, a significant correlation
between deposited dose and complaints can be found in the
inferior part of the rectum, over the entire circumference. After
evaluating the dataset by treatment group, similar characteristics
are found for the groups separately, but only reach significance
for the CTRT group (Supplementary S.4 and S.5). The DSMs for
bowel cramps and fecal leakage do not show significant areas,
before and after stratification.
To eliminate the possibility of confounding due to an increased
dose deposition in the central (high) dose region of the rectum
DSMs, a heat map of the correlation matrix of the DSM evaluation
points is displayed in the Supplementary S.3. From this figure it can
be deduced that no correlation higher than 0.5 can be found
between points located in the inferior part of the rectum and the
anterior part of the rectum, indicating a sole contribution of dose
to the inferior part of the rectum to diarrhea complaints.is defined to be the maximum deterioration from baseline at any point in the acute
Fig. 2. Dose volume histograms for rectum (relative) and bowel bag (absolute). The upper row represents the histograms for rectum, the bottom for bowel bag. The
histograms are depicted for the three toxicity endpoints as defined before and for all individual patients. In red the median curve for patients reporting toxicity and for
patients who do not is shown. The Wilcoxon p-value is computed for each dose point of 1 Gy between the two groups. The right (logarithmic) y-axis corresponds to the
Wilcoxon p-value, the blue dotted line represents p = 0.05.
Table 1
Results of the univariate analysis for diarrhea symptoms within the LACC-cohort. The toxicity incidence is given as the number of reported toxicities within the (sub)cohort over
the total number of patients. Rows containing p-values smaller than or equal to 0.2 have displayed odds ratios.
Toxicity incidence Diarrhea
All patients CTRT NeoCT + HTRT
61/103 47/71 14/32
OR (CI) p-value OR (CI) p-value OR (CI) p-value
Age* 1.02 (0.99–1.05) 0.30 1.03 (0.99–1.06) 0.18 1.00 (0.95–1.06) 0.94
Nullipara+ – NS – NS – NS
Prior abdominal surgery+ – NS – NS – NS
BMI* – NS – NS – NS
Smoker+ – NS – NS – NS
OTT* – NS – NS – NS
NeoCT + HTRT+ 0.39 (0.17–0.93) 0.03 N/A N/A N/A N/A
VMAT + – NS – NS – NS
Prone+ 0.57 (0.26–1.27) 0.17 0.52 (0.19–1.41) 0.19 1.15 (0.27–4.87) 0.85
Mover+ – NS – NS – NS
PTV volume* 1.17 (1.01–1.37) 0.03 1.24 (1.01–1.53) 0.03 1.16 (0.91–1.47) 0.20
PTV/BMI* 1.02 (0.99–1.06) 0.12 1.03 (0.98–1.08) 0.25 1.03 (0.99–1.08) 0.13
PIBS+2cm* – NS – NS – NS
PIBS* 0.98 (0.95–1.00) 0.07 1.00 (0.97–1.03) 0.87 0.99 (0.94–1.04) 0.63
PIBS-2cm* 0.98 (0.96–1.01) 0.12 0.99 (0.97–1.02) 0.72 1.00 (0.96–1.04) 0.98
LBRectum-PTV* 0.95 (0.92–0.99) <0.01 1.00 (0.98–1.02) 0.49 1.01 (0.96–1.07) 0.62
IsoV15Gy* – NS – NS – NS
IsoV20Gy* 1.01 (0.99–1.04) 0.32 1.03 (0.99–1.06) 0.15 1.01 (0.97–1.05) 0.70
IsoV25Gy* 1.02 (0.99–1.06) 0.20 1.05 (0.99–1.11) 0.05 1.01 (0.96–1.07) 0.72
IsoV30Gy* 1.04 (0.99–1.10) 0.12 1.08 (0.99–1.17) 0.07 1.03 (0.95–1.13) 0.42
IsoV35Gy* 1.06 (0.99–1.14) 0.07 1.10 (1.00–1.21) 0.05 1.06 (0.94–1.18) 0.30
IsoV40Gy* 1.08 (0.99–1.17) 0.07 1.12 (1.00–1.26) 0.04 1.06 (0.90–1.22) 0.36
IsoV45Gy* 1.08 (0.97–1.21) 0.15 1.14 (0.97–1.33) 0.09 1.09 (0.91–1.29) 0.32
Dmean, Rectum* 1.13 (1.01–1.26) 0.03 1.18 (1.02–1.36) 0.03 1.00 (0.81–1.24) 1.00
Dmean, Bowelbag* – NS – NS – NS
BMI = Body Mass Index, CC – index = Charlson Comorbidity index, WHO score = World Health Organization, OTT = Overall Treatment Time, VMAT = Volumetric Modulated Arc
Therapy (compared to Intensity-Modulated Radiation Therapy), PTV = Planning Target Volume in cc (OR defined per 100 cc), PTV/BMI = ratio of the Planning Target Volume
over the Body Mass Index, PIBS = Posterior–Inferior Border of Symphysis, anatomical vaginal reference point, LB = Lower Bound, the cranial–caudal distance between rectum
structure and PTV structure in mm, IsoVxGy = Isodose Volume in cc of the body receiving  Gy or more (OR defined per 100 cc), Dmean,x = the mean dose to structure x, NS = p-
value higher than 0.2, OR = Odds Ratio, CI = 95% Confidence Interval. Symbols: * for continuous variables, + for binary variables.
Statistical significance was defined as p < 0.05.
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Fig. 3. Dose surface maps as constructed for rectum. Rows represent the results for the three different toxicity endpoints. Columns represent the average DSM for patients
reporting toxicity, the average DSM for patients not reporting toxicity, the subtraction of the average toxicity DSM minus the average no toxicity DSM, for each endpoint
respectively. The solid line represents the significant region of the 95%-percentile of the corrected dose-difference data. The line shows consistent (significant) deviations
between groups for diarrhea symptoms.
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In this research we investigated the correlation between
patient-reported acute GI toxicity and clinical and dosimetric
factors, in a prospective LACC-cohort treated with a plan-library-
based PotD approach. A relationship was found between PTV
volume and diarrhea symptoms, indicating the benefit of our PotD
approach which minimizes the PTV volume. The results also
suggest that a higher dose to the inferior rectum causes a higher
incidence of diarrhea complaints. No correlation between dose to
the bowel bag and diarrhea was found in our results, which is in
contrast with previous reports.
The relationship between small bowel dose and GI toxicity in
the acute phase has been previously demonstrated by Chen et al.
for rectal cancer, by Han et al. for anal and perianal cancer and Sini
et al. for prostate cancer [25–27]. Chen et al. found a significant
association between overall (patient-reported) gastrointestinal
symptoms and V15Gy of the small bowel. Han et al. found a signif-
icant correlation between small bowel dose and physician-graded
diarrhea. However, a comparison of our findings with the results
of these studies might not be entirely justified, as the work of Chen
et al. and Han et al. investigated tumor sites that were part of the
(ano)rectum structure. Interestingly, the significant correlation
Han et al. found between small bowel dose and physician-graded
diarrhea was not observed for patient-reported endpoints [26].
Jensen et al. confirmed this grading difference by describing a poor
correlation between patient-reported EORTC-scored diarrhea and
physician-reported CTCAE-scored diarrhea for cervical cancer
patients [28]. Our study used patient-reported endpoints, which
might therefore explain why previously reported bowel bag
dose–volume parameters did not predict toxicity outcomes in
our cervical cancer cohort. On the other hand, a significant rela-
tionship between small bowel dose and patient-reported GI toxic-
ity as reported by Sini et al. was not found in our cohort. In thiscase, the mere difference between patient- versus physician-
reported outcome does not explain these findings. One other
hypothesis to explain these diverging results is the difference in
contour delineation. Our results are based on the bowel bag struc-
ture, which differs from the small bowel structure that is reported
amongst others by Sini et al. Different definitions of bowel delin-
eation have been demonstrated to lead to significant dose–re-
sponse relationships differences, also in gynecological cohorts
specifically [2,3]. To summarize, several methodological choices
regarding target group, patient- versus physician-reporting and
bowel delineation method could explain why our results did not
show previously reported correlations between bowel dose and
diarrhea symptoms.
Our results suggest a correlation between diarrhea symptoms
and the dose locally received by the inferior part of rectum. Com-
parable results were found by Wortel et al., who reported a corre-
lation between higher doses to the inferior part of the rectum and
patient-reported acute diarrhea symptoms [9]. Of note, Wortel
et al. reported an incidence of diarrhea of 14%, versus 59% in our
study. This could be explained by the bigger field sizes for radio-
therapy and the administration of chemotherapy for the LACC-
cohort. The similarity in spatial effect for both studies is neverthe-
less remarkable, since results are reported for a different gender,
tumor site and age group.
Two treatment groups have been included in this study, consist-
ing out of a CTRT group and a NeoCT + HTRT group. The groups
were selected for analysis as they make up the first line of care
for LACC-patients in our institute. Both groups received
platinum-based chemotherapy, administered either before
(NeoCT + HTRT group) or during (CTRT group) radiation treatment.
Baseline values for the endpoints are not statistically different for
both groups (Supplementary S.2). On the other hand, differences
in the incidence of diarrhea symptoms between both groups indi-
cate that the administration of chemotherapy during radiation
D.M.W. Reijtenbagh et al. / Radiotherapy and Oncology 148 (2020) 38–43 43treatment might have a (radio)sensitizing effect on bowel or rec-
tum mucosa. The PTV volume is significant within the CTRT group
for diarrhea symptoms, possibly indicating a benefit for our PotD
approach [29]. By further reducing the PTV volume, e.g. by expand-
ing the plan library, a reduction in diarrhea complaints might be
achieved [30]. Furthermore, no difference in toxicity was found
for mover and non-mover patients, which also suggests that the
PotD approach leads to the desired results. Indeed, non-mover
patients receive smaller planning target volumes compared with
population-based approaches due to the creation of the ITV – as
applied by other institutes. Mover patients require bigger ITVs to
encompass the bladder-related motion, but this is mitigated by
the use of a plan library where the ITV is split in multiple (smaller)
ITVs. This greatly reduces the overall irradiated volume compared
to a fully encompassing ITV-based plan. As a consequence, both
mover and non-mover patients benefit from our plan-library
approach.
It is unclear why PTV volume does not reach significance in the
NeoCT + HTRT group. The smaller cohort size could be a reason,
and more research is needed for specific effects within this treat-
ment group. The current recommendation of care for LACC-
patients is radiotherapy with concomitant chemotherapy, but
studies have shown (additional) benefit of the administration of
deep hyperthermia [22,31]. As deep hyperthermia for LACC-
patients is not widely applied, no literature is available for compar-
ison with our results. Further research is necessary to support the
findings for this treatment group.
In conclusion, we showed a correlation between PTV volume
and patient-reported acute diarrhea symptoms, as well as a spatial
dependency of rectal dose for these symptoms. To our knowledge,
this is the first study demonstrating this analysis in the context of a
LACC-cohort in the acute phase of the treatment for GI-related tox-
icity. The results justify current investments in adaptive strategies,
as smaller PTV volumes appear to correlate to fewer diarrhea com-
plaints. We aim to validate the findings prospectively in future
studies. We hope the results presented in this paper can serve as
a starting point to decrease in toxicity burden for LACC-patients
in both the acute and late phase of their treatment.Conflicts of interest
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